-
Something wrong with this record ?
Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma
Reiniš, M.
Current opinion in molecular therapeutics.
2007 ;
9 (3) :
291-298.
Language English Country Great Britain
Persistent link
https://www.medvik.cz/link/bmc10000869
- MeSH
- Hemocyanins immunology MeSH
- Immunoglobulin Idiotypes immunology MeSH
- Immunotherapy methods MeSH
- Clinical Trials, Phase II as Topic MeSH
- Clinical Trials, Phase III as Topic MeSH
- Humans MeSH
- Lymphoma, Non-Hodgkin immunology prevention & control therapy MeSH
- Drug Evaluation, Preclinical MeSH
- Cancer Vaccines immunology adverse effects therapeutic use MeSH
- Randomized Controlled Trials as Topic MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
Favrille Inc is developing FavIld, a patient-specific immunotherapy combining tumor-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. A phase III clinical trial in follicular B-cell non-Hodgkin's lymphoma is underway.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10000869
- 003
- CZ-PrNML
- 005
- 20120709213958.0
- 008
- 100114s2007 xxk e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Reiniš, Milan $7 xx0083033
- 245 10
- $a Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma / $c Reiniš, M.
- 314 __
- $a Academy of Sciences of the Czech Republic, Institute of Molecular Genetics, Videnská 1083, Prague 4, CZ-14220, Czech Republic. reinis@img.cas.cz
- 520 9_
- $a Favrille Inc is developing FavIld, a patient-specific immunotherapy combining tumor-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. A phase III clinical trial in follicular B-cell non-Hodgkin's lymphoma is underway.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové vakcíny $x imunologie $x škodlivé účinky $x terapeutické užití $7 D019496
- 650 _2
- $a klinické zkoušky, fáze II jako téma $7 D017322
- 650 _2
- $a klinické zkoušky, fáze III jako téma $7 D017326
- 650 _2
- $a preklinické hodnocení léčiv $7 D004353
- 650 _2
- $a hemokyanin $x imunologie $7 D006433
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiotypy $x imunologie $7 D007130
- 650 _2
- $a imunoterapie $x metody $7 D007167
- 650 _2
- $a nehodgkinský lymfom $x imunologie $x prevence a kontrola $x terapie $7 D008228
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 773 0_
- $w MED00173598 $t Current opinion in molecular therapeutics $g Roč. 9, č. 3 (2007), s. 291-298 $x 1464-8431
- 910 __
- $a ABA008 $b x $y 8
- 990 __
- $a 20100114083259 $b ABA008
- 991 __
- $b ABA008 $a 20120709213933
- 999 __
- $a ok $b bmc $g 703597 $s 566038
- BAS __
- $a 3
- BMC __
- $a 2007 $b 9 $c 3 $d 291-298 $m Current opinion in molecular therapeutics $x MED00173598
- LZP __
- $a 2010-b1/vtme
